Thu.May 16, 2024

article thumbnail

Q&A: How Coffee Helped This Pharmacy Improve Front-End Sales

Drug Topics

Chris Schaffner, owner of Schaffner Pharmacy and Apothecary Coffee in Sedro-Woolley, Washington, sat down with Drug Topics to discuss his joint business venture.

201
201
article thumbnail

The only tribal medical school in the U.S. graduates its first Native American doctors

STAT

There are so few Indigenous physicians in the United States — just 0.3% of doctors — that their numbers barely show up in charts and graphs depicting the diversity of the medical workforce. But as of Thursday, there will be at least nine more. Thursday is graduation day for the first class of the nation’s only tribally affiliated medical school, the Oklahoma State University College of Osteopathic Medicine at the Cherokee Nation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Once-Weekly Insulin for T2D Shows Positive Topline Results in Phase 3 Clinical Trial Program

Drug Topics

Efsitora (efsitora alfa) from Eli Lilly met its primary endpoint of non-inferior A1C reduction compared to insulin degludec and insulin glargine in 2 phase 3 studies.

123
123
article thumbnail

In military medicine, study shows rank and race affect care

STAT

Higher ranking military officers receive more resources and better care than low ranking military officers, according to an analysis of 1.5 million military ER visits published Thursday in the journal Science. The study also showed that white physicians expended less effort on Black patients, even when rank was taken into account: Higher ranking Black officers received care from white physicians that was similar to that received by lower ranking white officers.

144
144
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

May is Hepatitis Awareness Month

Pharmacy Times

Hepatitis Awareness Month is designed to raise awareness of viral hepatitis and promote testing and vaccination while decreasing the stigma against the virus.

Vaccines 138
article thumbnail

Opinion: As childhood asthma worsens, insurers restrict access to an essential medication

STAT

As pediatricians who take care of children in the inpatient, emergency, and primary care settings, we are alarmed by the recent trend of families having to go without basic medications to control their child’s asthma. At least seven children have died due to uncontrolled asthma this year in the Philadelphia region, a dramatic increase from prior years.

Insurance 140

More Trending

article thumbnail

FDA Grants Accelerated Approval for Liso-Cel in Patients With Relapsed or Refractory Follicular Lymphoma

Pharmacy Times

The indication is for adult patients who have received at least 2 prior lines of systemic therapy and is based on the response rate and duration of response shown in a phase 2 trial.

FDA 122
article thumbnail

Government Dedicates Nearly $200 Million to Contain US Bird Flu Outbreak

Drug Topics

Over half of the money is set to assist the overall effort to stop the virus, while the remaining funds will go to dairy farms affected by the bird flu outbreak.

112
112
article thumbnail

Opinion: Treating chronic pain requires much more than medications

STAT

There’s a lot of buzz surrounding the new non-addictive pain pill that is up for FDA approval. It works as well as opioids for treating acute pain, and shows promise in treating chronic neuropathic pain as well. We are constantly getting messages from patients we are treating for all different types of chronic pain — arthritis, back pain, fibromyalgia, and pain we just can’t seem to figure out — along the lines of “Doc, have you heard about it?

FDA 125
article thumbnail

Transcarent unveils new gen AI-enabled platform WayFinding

Fierce Healthcare

Earlier this month, Transcarent teased that it was betting big on artificial intelligence as it banked a $126 million funding round. | Earlier this month, Transcarent teased that it was betting big on artificial intelligence as it banked a $126 million funding round. Now, it's unveiling WayFinding, a new platform that leans on generative AI to connect members with benefits navigation, clinical guidance and care delivery services all in one place.

124
124
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

STAT+: Microsoft’s Peter Lee says ChatGPT shouldn’t be used for initial diagnosis

STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

123
123
article thumbnail

Mayo Clinic Oncology Pharmacist Discusses Bridging Clinical Research and Pharmacy Practice

Pharmacy Times

Scott Soefje highlights how oncology pharmacists can advance patient-centered care and drive innovation in clinical research.

article thumbnail

STAT+: Analysis of pharmaceutical R&D ranks Novo Nordisk and Johnson & Johnson above their peers

STAT

When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis. But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca. The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STA

120
120
article thumbnail

In Big Pharma's growth rankings, Lilly took top spot from Novo Nordisk in Q1

Fierce Pharma

The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. With 18 of the industry’s top 25 companies achieving year-over-year revenue gains, Q1 came close to matching the final quarter of last year, when 21 of the top 25 companies showed increases.

108
108
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

STAT+: Lilly’s weekly insulin works as well as daily products, new studies show

STAT

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk. In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.

117
117
article thumbnail

FT US Pharma and Biotech Summit: Live coverage

pharmaphorum

Explore innovation, investment, and policies at the US Pharma and Biotech Summit 2024. Join industry leaders, regulators, and investors to discuss trends shaping healthcare.

108
108
article thumbnail

Amid backlash to harm reduction, addiction experts warn against reprising ‘war on drugs’

STAT

SAN FRANCISCO — Amid what feels like an ever-worsening drug crisis here, locals and politicians alike are fed up. Overdose death rates remain near all-time highs. The Tenderloin, a historic downtown neighborhood, remains rife with open-air substance use and drug dealing. Public health officials are increasingly at a loss. In recent years, much of the backlash has come to focus on harm reduction, the philosophy and practice of reducing the most acute drug-related harms without expecting ab

110
110
article thumbnail

Can you take Breztri Aerosphere for asthma?

The Checkup by Singlecare

Breztri Aerosphere is an inhaled medication in the form of a metered dose inhaler. It contains three ingredients: budesonide, formoterol fumarate, and glycopyrrolate. It is approved by the Food & Drug Administration (FDA) for long-term treatment of adults with chronic obstructive pulmonary disease (COPD). COPD is a long-term condition that includes either or both of the following: Chronic bronchitis : Long-term bronchial inflammation that causes individuals to have a productive cough for mo

article thumbnail

STAT+: PDS Biotech’s survival benefit is absurdly overstated

STAT

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up  here  to get it delivered every Thursday to their inbox. Hello, friends! I’m in San Francisco for the STAT Breakthrough Summit. Later today, I’ll be “fireside chatting” with Cytokinetics CEO Robert Blum.

104
104
article thumbnail

FDA snubs another China-made PD-1 with rejection of Elevar, Hengrui's liver cancer combo

Fierce Pharma

China-made PD-1 inhibitors just can’t get a clean pass through the FDA. | China-made PD-1 inhibitors continue to struggle at the FDA. This week, the U.S. agency rejected Elevar Therapeutics and Jiangsu Hengrui Pharma's PD-1 combination in liver cancer.

FDA 103
article thumbnail

Kansas Medicaid selects UnitedHealth, Blue Cross and Centene

Fierce Healthcare

Three managed care organizations were recently selected to serve Kansas Medicaid members, the state’s department of health and environment announced. | KanCare, the state Medicaid program, opted against awarding a bid to Aetna Better Health of Kansas.

99
article thumbnail

STAT+: Obesity drug from Roche succeeds in early test, sending company shares up

STAT

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.   The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said.

99
article thumbnail

Fire breaks out at Novo production hub: None injured and construction timelines likely unaffected, company says

Fierce Pharma

A fire broke out Thursday on the roof of a building under construction at Novo Nordisk’s key manufacturing hub in Kalundborg, Denmark, where the drugmaker is currently charting a multi-year expansi | A fire broke out Thursday on the roof of a building under construction at Novo Nordisk’s key manufacturing hub in Kalundborg, Denmark, where the drugmaker is currently charting a multi-year expansion to boost capacity for its blockbuster diabetes and obesity drugs.

98
article thumbnail

Second House panel advances two-year telehealth extension

STAT

WASHINGTON — A House subcommittee on Thursday advanced legislation that would extend some pandemic-era telehealth policies in Medicare for two years, bringing the panel’s approach in line with another committee. During the pandemic, Congress extended flexibilities that changed what kinds of care Medicare beneficiaries could receive over telehealth and where.

97
article thumbnail

GSK pledges £45m to support global AMR prevention

European Pharmaceutical Review

GSK’s funding would be accessible for approved projects including those that employ new technology such as AI to improve interpretation and use complex scientific data” GSK is set to become the first founding partner of the Fleming Initiative. According to GSK, The Fleming Initiative’s will gather “world-class scientific, technology, policy and behavioural science expertise with clinical experience in a global network of centres to find, test, and scale solutions to [antimicrobial resistan

96
article thumbnail

12 Questions with Kirsten Parr

pharmaphorum

Get to know Kirsten Parr through 12 insightful questions as she shares her experiences and insights while working at IPG Health Medical Communications.

article thumbnail

New EVP, Teva Global Operations appointed

European Pharmaceutical Review

Matthew Shields has been appointed as Executive Vice President of Teva Pharmaceutical Industries Ltd.’s manufacturing and supply division. His position within Teva Global Operations will commence on 3 June 2024. He will be part of the company’s Executive Leadership Team and be based at Teva’s US headquarters. Mr Shields stated that he is “honoured” to take on his new role.

95
article thumbnail

TIGIT developer iTeos raises $120m, and other financings

pharmaphorum

Notable biotech financings in the last week include a $120m direct offering for iTeos, and private rounds for Lycia, Attovia, Ajax, and CinDome

106
106
article thumbnail

Listen: Live! From the STAT Breakthrough Summit West

STAT

On this week’s “Readout LOUD,” we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme this year, everywhere, so on that note, we chat with our AI correspondent — and recent Pulitzer finalist — Casey Ross, who sat down on stage to discuss AI-centered drug discovery with both NVIDIA and Google-backed Isomorphic Labs.

93
article thumbnail

How does Farxiga help kidneys?

The Checkup by Singlecare

Kidney disease is much more common than some may realize. The Centers for Disease Control and Prevention (CDC) estimates that 1 in 7 U.S. adults have chronic kidney disease , and 90% do not know that they have it. Luckily, we are gaining tools to help damaged kidneys, and Farxiga (dapagliflozin) is one of the medications in our toolbox now. As a sodium-glucose cotransporter 2 (SGLT2) inhibitor , it can help to lower the strain on renal blood vessels, slowing the progression of kidney disease.

Dosage 92
article thumbnail

Advise Patients About Travel Vaccines

Pharmacy Times

As Summer Approaches, Many Will Be Planning Vacations and Trips Abroad

Vaccines 132
article thumbnail

Blackstone wants in on red-hot immunology market

STAT

The need-to-know this morning Biogen  and  Ionis Pharmaceuticals  are  ending their development  of an experimental drug for ALS based on results of a Phase 1/2 trial. Johnson & Johnson  said it will  acquire   Proteologix , a privately-held biotech focused on immune-mediated diseases, for $850 million with potential for additional milestone payments.

article thumbnail

Conference report: Reuters Pharma Europe

pharmaphorum

In this special edition of the pharmaphorum podcast, the tables have turned as Jonah Comstock puts editors Eloise McLennan and Nicole Raleigh in the hot seat to discuss the biggest trends and talking points from last month’s Reuters Pharma Europe 2024 in Barcelona.

88
article thumbnail

Tracking the opioid lawsuit settlements amidst calls for oversight

Pharmaceutical Technology

The US National Opioid Settlement is distributing more than $54 billion to communities grappling with the opioid crisis.

105
105